Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. announced a reduction in shareholding by Shanghai Tanying Investment Partnership, which previously held over 6.96% of the company’s total share capital. This decision follows the maturity of the fund and liquidity arrangements, impacting the company’s shareholder structure and potentially influencing market perceptions of its financial strategy.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the research, development, and commercialization of innovative therapies. The company is listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange and is involved in the production of biologics and small molecule drugs.
Average Trading Volume: 5,829,847
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.44B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.